知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.036 seconds)

    Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
    11.
    发明授权
    Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass 失效
    用于诊断和治疗关节炎疾病和调节骨量的方法和组合物

    公开(公告)号：US07005274B1

    公开(公告)日：2006-02-28

    申请号：US09661848

    申请日：2000-09-14

    Applicant: Robert Terkeltaub ,  Anne N. Murphy ,  James A. Dykens ,  Soumitra S. Ghosh ,  Robert E. Davis ,  Andrew E. Granston, Jr.

    Inventor： Robert Terkeltaub ,  Anne N. Murphy ,  James A. Dykens ,  Soumitra S. Ghosh ,  Robert E. Davis ,  Andrew E. Granston, Jr.

    IPC: C12Q1/02

    CPC classification number: G01N33/5088 ,  G01N33/6887 ,  G01N2333/4722 ,  G01N2333/495 ,  G01N2333/78 ,  G01N2400/40 ,  G01N2800/102 ,  G01N2800/105

    Abstract: The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

    Abstract translation: 本发明涉及通过比较改变的线粒体功能的一个或多个指示剂的水平，用于早期发现人类关节炎疾病的风险的改进的诊断方法以及用于治疗关节炎疾病的治疗剂的筛选测定。 改变线粒体功能的指标包括线粒体酶和ATP生物合成因子等酶。 改变的线粒体功能的其他指标包括线粒体质量，线粒体数量和线粒体DNA含量，细胞内升高的钙和凋亡细胞的反应以及自由基生成。 还提供了用于治疗和分层人类患者的方法，这些方法涉及公开的改变的脑膜功能指标。

    Mitochondria protecting agents for treating mitochondria associated diseases
    12.
    发明授权
    Mitochondria protecting agents for treating mitochondria associated diseases 失效
    线粒体保护剂用于治疗线粒体相关疾病

    公开(公告)号：US06498191B2

    公开(公告)日：2002-12-24

    申请号：US09733271

    申请日：2000-12-07

    Applicant: Soumitra S. Ghosh ,  Scott W. Miller ,  Robert E. Davis ,  Walter H. Moos

    Inventor： Soumitra S. Ghosh ,  Scott W. Miller ,  Robert E. Davis ,  Walter H. Moos

    IPC: A61K31225

    CPC classification number: A61K31/155 ,  A61K31/00 ,  A61K31/05 ,  A61K31/06 ,  A61K31/136 ,  C07C39/08 ,  C07C39/11 ,  C07C39/19 ,  C07C69/017 ,  C07C215/78 ,  C07C215/80 ,  C07C217/84 ,  C07C279/18 ,  C07D215/20 ,  C07D311/72

    Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

    Abstract translation: 本发明一般涉及用于治疗线粒体功能障碍导致组织变性的线粒体保护剂，更具体地涉及与其相关的化合物，组合物和方法。 本发明的方法涉及向有需要的温血动物施用药学有效量的线粒体保护剂，本发明的组合物含有与药学上可接受的载体或稀释剂组合的线粒体保护剂。 可以通过本发明治疗的线粒体相关疾病包括（但不限于）阿尔茨海默氏病，糖尿病，帕金森病，神经元和心脏缺血，亨廷顿病和中风。

    End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids
    14.
    发明授权
    End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids 失效
    将寡核苷酸末端连接到用于捕获和检测核酸的聚丙烯酰胺固体支持物上

    公开(公告)号：US5478893A

    公开(公告)日：1995-12-26

    申请号：US102474

    申请日：1993-08-05

    Applicant: Soumitra S. Ghosh ,  Eoin D. Fahy

    Inventor： Soumitra S. Ghosh ,  Eoin D. Fahy

    IPC: C07H21/00 ,  C12Q1/68 ,  C08F120/56 ,  C07H21/02 ,  C07H21/04

    CPC classification number: C07H21/00

    Abstract: Methods for covalent attachment of oligonucleotides to solid supports such that substantially all of the oligonucleotides are attached via their 5'-ends are provided. The solid supports with attached oligonucleotides are produced. Thiol-oligonucleotides are attached to bromoacetyl-derivatized polyacrylamide supports, or conversely, bromoacetyl-oligonucleotides are immobilized on thiol-polyacrylamide supports. In a further aspect, bromoacetyl-derivatized oligonucleotides, and polyacrylamide supports with linked oligonucleotides produced by coupling bromoacetyl-derivatized oligonucleotides with thiol-derivatized polyacrylamide solid supports or by coupling thiol-derivatized oligonucleotides with bromoacetyl-derivatized polyacrylamide supports as well as methods for capture of nucleic acids by oligonucleotides attached to polyacrylamide solid supports, either by direct capture or in sandwich hybridization formats are provided.

    Abstract translation: 提供了将寡核苷酸共价连接到固体支持物的方法，使得基本上所有的寡核苷酸通过其5'-末端连接。 产生具有连接的寡核苷酸的固体支持物。 硫醇寡核苷酸连接到溴乙酰基衍生的聚丙烯酰胺载体上，或者相反地，溴乙酰基寡核苷酸固定在硫醇 - 聚丙烯酰胺载体上。 在另一方面，溴乙酰基衍生的寡核苷酸和具有通过将溴乙酰基衍生的寡核苷酸与硫醇衍生的聚丙烯酰胺固体支持物偶联或通过将硫醇衍生的寡核苷酸与溴乙酰基衍生的聚丙烯酰胺载体偶联产生的链接寡核苷酸的聚丙烯酰胺载体以及捕获 提供了通过直接捕获或以夹心杂交形式连接到聚丙烯酰胺固体支持物上的寡核苷酸的核酸。

    C-terminal amidation of polypeptides
    15.
    发明授权
    C-terminal amidation of polypeptides 有权
    多肽的C-末端酰胺化

    公开(公告)号：US09249181B2

    公开(公告)日：2016-02-02

    申请号：US13822821

    申请日：2011-09-08

    Applicant: Chengzao Sun ,  Behrouz Bruce Forood ,  Gary Luo ,  Soumitra S. Ghosh

    Inventor： Chengzao Sun ,  Behrouz Bruce Forood ,  Gary Luo ,  Soumitra S. Ghosh

    IPC: C07K1/00 ,  C07K1/107 ,  C07D311/88 ,  C07C211/27

    CPC classification number: C07K1/003 ,  C07C211/27 ,  C07D311/88 ,  C07K1/107

    Abstract: There are provided compounds and methods for amidating the C-terminus of a polypeptide. The methods include reacting a polypeptide which includes a C-terminal thioester or C-terminal selenoester with any one of a defined set of auxiliary molecules under conditions suitable to produce a polypeptide adduct which includes the auxiliary molecule chemically bound at the C-terminal of the polypeptide. The auxiliary molecule can be a substituted or unsubstituted 2-phenyl-2-amino ethanethiol, a substituted or unsubstituted 2-phenyl-2-amino ethaneselenol, or a substituted xanthene. In the subsequent step, a portion of the auxiliary molecule is removed from the C-terminal of the polypeptide adduct and leaving the amide nitrogen under conditions suitable to form a C-terminal free amide polypeptide.

    Abstract translation: 提供了用于酰胺化多肽的C末端的化合物和方法。 所述方法包括在适于产生多肽加合物的条件下使包含C-末端硫酯或C-末端硒酯的多肽与定义的一组辅助分子中的任何一种反应，所述多肽加合物包括在C末端化学键合的辅助分子 多肽。 辅助分子可以是取代或未取代的2-苯基-2-氨基乙硫醇，取代或未取代的2-苯基-2-氨基乙基硒酚或取代的呫吨。 在随后的步骤中，一部分辅助分子从多肽加合物的C末端除去，并在适于形成C末端游离酰胺多肽的条件下离开酰胺氮。

    Pancreatic polypeptide family motifs and polypeptides comprising the same
    16.
    发明授权
    Pancreatic polypeptide family motifs and polypeptides comprising the same 失效
    胰多肽家族基序和包含其的多肽

    公开(公告)号：US08603969B2

    公开(公告)日：2013-12-10

    申请号：US11055098

    申请日：2005-02-11

    Applicant: Odile Esther Levy ,  Carolyn M. Jodka ,  Soumitra S. Ghosh ,  David G. Parkes ,  Richard A. Pittner ,  Lawrence J. D'Souza ,  John S. Ahn ,  Kathryn S. Prickett

    Inventor： Odile Esther Levy ,  Carolyn M. Jodka ,  Soumitra S. Ghosh ,  David G. Parkes ,  Richard A. Pittner ,  Lawrence J. D'Souza ,  John S. Ahn ,  Kathryn S. Prickett

    IPC: A61K38/22

    CPC classification number: C07K14/575 ,  A61K38/00 ,  C07K14/475

    Abstract: The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

    Abstract translation: 本发明涉及新型胰腺多肽家族（“PPF”）多肽。 本发明的PPF多肽通常包括至少两个PPF基序，其长度与PYY（3-36）具有至少50％的序列同一性，并且通常至少部分地保留PP，PYY的生物学活性或 NPY。 本发明优选的PPF多肽是在本文所述测定之一（优选食物摄取，胃排空，胰腺分泌或重量减轻试验）中具有效力的那些，其大于PP，NPY，PYY或PYY的效力（ 3-36）。 一方面，本发明的PPF多肽包括新的PYY类似物多肽。 在另一方面，本发明的PPF多肽包括PPF嵌合多肽，其包括与第二PP家族多肽连接的PP家族多肽的片段，其中第一和第二片段中的每一个包括PPF基序。 还公开了使用本发明的PPF多肽的方法和包括本发明的PPF多肽的药物组合物。

    Aryl-N-cyanoguanidines and methods related thereto
    19.
    发明授权
    Aryl-N-cyanoguanidines and methods related thereto 失效
    芳基-N-氰基胍及其相关方法

    公开(公告)号：US06562821B2

    公开(公告)日：2003-05-13

    申请号：US10085119

    申请日：2002-02-27

    Applicant: Soumitra S. Ghosh ,  Tomas R. Szabo

    Inventor： Soumitra S. Ghosh ,  Tomas R. Szabo

    IPC: C07C27928

    CPC classification number: A61K31/5375 ,  A61K31/155 ,  C07C279/28

    Abstract: Compounds, compositions and methods treating arthritic disorders such as osteoarthritis or rheumatoid arthritis, and for treating other diseases associated with altered mitochondrial function, such as cancer, psoriasis, stroke, Alzheimer's Disease and diabetes. The compounds of this invention have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1-5 are as defined herein. The methods of this invention are directed to administering to a warm-blooded animal in need thereof an effective amount of a compound of structure (I), typically in the form of a pharmaceutical composition.

    Abstract translation: 治疗关节炎疾病如骨关节炎或类风湿性关节炎的化合物，组合物和方法，以及用于治疗与线粒体功能改变相关的其它疾病，例如癌症，牛皮癣，中风，阿尔茨海默氏病和糖尿病。 本发明的化合物具有以下结构（I）：包括其立体异构体，前药和药学上可接受的盐，其中R1-5如本文所定义。 本发明的方法涉及向有需要的温血动物施用有效量的结构式（I）的化合物，通常为药物组合物的形式。

Patent Agency Ranking